When the FDA gives approval for the first drug to be used for agitation (brexpiparazole) in Alzheimer's and dementia patients, there's also fair warning for the hidden side effects along with mortality risk. Mary Anne Oglesby-Sutherly and Sue Duffield have an honest and informative discussion about the pros and cons of using this type of drug in a brain that has a disease, and not just depression. The use of the word "Care Partner" is also described, as families, professionals and the medical profession try and should work together to do what's best for the person with dementia or Alzheimer's. Mary Anne reads directly from the press release from the agency as to the indications, dosage, and side effects of this approved medication. This is not new information, but it is a first for this drug's approval. Understanding your loved one's behavior, as a caregiver and care partner, could be the greatest therapy, instead of drugs that carry such risks. www.verandaministries.org